BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
Matthias Scheffler
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim
Masyar Gardizi
Other Remuneration - Boehringer Ingelheim
Marc Christiaan Allardt Bos
No relevant relationships to disclose
Lucia Nogova
No relevant relationships to disclose
Sebastian Michels
No relevant relationships to disclose
Thorsten Persigehl
No relevant relationships to disclose
Martin L. Sos
No relevant relationships to disclose
Felix Dietlein
No relevant relationships to disclose
Thomas Zander
Research Funding - Novartis
Juergen Wolf
Consultant or Advisory Role - Boehringer Ingelheim; Novartis
Honoraria - Boehringer Ingelheim; Novartis
Research Funding - Boehringer Ingelheim; Novartis